US pharmaceutical company AstraZeneca Plc (LON: AZN) (STO: AZN) announced on 23 November 2020 that its experimental COVID-19 vaccine has shown an average efficacy of 70% in its large scale trials, CNN reported on Monday.
This vaccine, developed with the University of Oxford, showed 90% efficacy in one dosing regimen and 62% efficacy in a second regimen, which averages to a 70% efficacy, AstraZeneca said.
In a news release, AstraZeneca said that its vaccine was "highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine."
According to the company, the interim analysis included a total of 131 COVID-19 cases.
This comes after Moderna announced earlier this month that its vaccine was 94.5% effective against COVID-19 and Pfizer announced its vaccine was 95% effective, CNN added.
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Valneva signs exclusive German vaccine distribution deal with CSL Seqirus